Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2021 Results Conference Call March 23, 2022 4:30 PM ET
Company Participants
Tim McCarthy - IR, LifeSci Advisors
Sergio Traversa - CEO
Maged Shenouda - CFO
Conference Call Participants
Andrew Tsai - Jefferies
Andrea Tan - Goldman Sachs
Joon Lee - Truist Securities
Yatin Suneja - Guggenheim
Jay Olson - Oppenheimer
Operator
Greetings, and welcome to the Relmada Therapeutics Fourth Quarter and Full Year 2021 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Tim McCarthy of LifeSci Advisors. Thank you, Tim. You may begin.
Tim McCarthy
Thank you, Paul, and thank you all for joining us this afternoon.
With me on today’s call are Chief Executive Officer, Sergio Traversa, and Chief Financial Officer, Maged Shenouda.
This afternoon, Relmada issued a news release providing a business update announcing financial results for the 3 and 12 months ended December 31, 2021. Please note that certain information discussed on the call today is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that during this call, Relmada’s management team will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the Company’s business. These forward-looking statements are qualified by the cautionary statements contained in Relmada’s press release issued today, and the Company’s SEC filings, including in the annual report on Form 10-K for the year ended December 30, 2020, and subsequent filings.
This conference call also contains time-sensitive information that is accurate only as of the date of this live broadcast, March 23, 2022. Relmada undertakes no
- Read more current RLMD analysis and news
- View all earnings call transcripts